1JKH

CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ)

Summary for 1JKH

• Entry DOI: 10.2210/pdb1jkh/pdb
• Related: 1C0T 1C0U 1C1B 1C1C 1DTQ 1DTT 1EP4 1FK9 1FKO 1FKP 1JLA 1JLB 1JLC 1JLE 1JLF 1JLG 1JLQ 1KLM 1REV 1RT1 1RT2 1RT3 1RT4 1RT5 1RT6 1RT7 1RTH 1RTI 1RTJ 1VRT 1VRU
• Descriptor: HIV-1 RT, A-CHAIN, HIV-1 RT, B-CHAIN, (-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE, ... (4 entities in total)
• Functional Keywords: hiv-1 reverse transcriptase, aids, non-nucleoside inhibitor, dmp-266, efavirenz, drug resistance mutations, drug design, transferase
• Biological source: HIV-1 M:B_HXB2R; More
• Cellular location: Matrix protein p17: Virion (Potential). Capsid protein p24: Virion (Potential). Nucleocapsid protein p7: Virion (Potential). Reverse transcriptase/ribonuclease H: Virion (Potential). Integrase: Virion (Potential): P04585 P04585
• Total number of polymer chains: 2
• Total formula weight: 116189.61

Authors

Ren, J.,Nichols, C.,Bird, L.,Chamberlain, P.,Weaver, K.,Short, S.,Stuart, D.I.,Stammers, D.K. (deposition date: 2001-07-12, release date: 2001-10-03, Last modification date: 2024-11-13)

Primary citation

Ren, J.,Nichols, C.,Bird, L.,Chamberlain, P.,Weaver, K.,Short, S.,Stuart, D.I.,Stammers, D.K.
Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
J.Mol.Biol., 312:795-805, 2001

PubMed Abstract: Mutations at either Tyr181 or Tyr188 within HIV-1 reverse transcriptase (RT) give high level resistance to many first generation non-nucleoside inhibitors (NNRTIs) such as the anti-AIDS drug nevirapine. By comparison second generation inhibitors, for instance the drug efavirenz, show much greater resilience to these mutations. In order to understand the structural basis for these differences we have determined a series of seven crystal structures of mutant RTs in complexes with first and second generation NNRTIs as well as one example of an unliganded mutant RT. These are Tyr181Cys RT (TNK-651) to 2.4 A, Tyr181Cys RT (efavirenz) to 2.6 A, Tyr181Cys RT (nevirapine) to 3.0 A, Tyr181Cys RT (PETT-2) to 3.0 A, Tyr188Cys RT (nevirapine) to 2.6 A, Tyr188Cys RT (UC-781) to 2.6 A and Tyr188Cys RT (unliganded) to 2.8 A resolution. In the two previously published structures of HIV-1 reverse transcriptase with mutations at 181 or 188 no side-chain electron density was observed within the p66 subunit (which contains the inhibitor binding pocket) for the mutated residues. In contrast the mutated side-chains can be seen in the NNRTI pocket for all seven structures reported here, eliminating the possibility that disordering contributes to the mechanism of resistance. In the case of the second generation compounds efavirenz with Tyr181Cys RT and UC-781 with Tyr188Cys RT there are only small rearrangements of either inhibitor within the binding site compared to wild-type RT and also for the first generation compounds TNK-651, PETT-2 and nevirapine with Tyr181Cys RT. For nevirapine with the Tyr188Cys RT there is however a more substantial movement of the drug molecule. We conclude that protein conformational changes and rearrangements of drug molecules within the mutated sites are not general features of these particular inhibitor/mutant combinations. The main contribution to drug resistance for Tyr181Cys and Tyr188Cys RT mutations is the loss of aromatic ring stacking interactions for first generation compounds, providing a simple explanation for the resilience of second generation NNRTIs, as such interactions make much less significant contribution to their binding.

PubMed: 11575933
DOI: 10.1006/jmbi.2001.4988

Experimental method

X-RAY DIFFRACTION (2.5 Å)